Overweight and obese patients have lower rate of remission at six and 12 months of follow-up

Studies show potential benefits of lambrolizumab, concurrent nivolumab and ipilimumab

Physicians often forced to compromise patient care

Improves survival in patients whose cancer is resistant to radioactive iodine treatment

Patient with metastatic lung adenocarcinoma initially responded but acquired resistance

Maintenance therapy linked to longer progression-free survival after surgery for advanced disease

And, similar disease control, less lymphedema for axillary radiotherapy vs. lymph node dissection

Longer progression-free survival, higher response rate for crizotinib versus standard chemo

No significant reduction in death, severe disability with intensive versus guideline-recommended tx

Patients receiving supplementation have reduced heart failure hospitalization, cardiovascular death

Significant prolongation of time to next respiratory hospitalization with antibiotics

Five-day systemic glucocorticoid tx non-inferior to 14-day tx for reexacerbations within 180 days

Improvements seen in lung function and inflammatory-associated biomarkers

Improvements in muscle strength, fatigue, quality of life for patients with stable Crohn's

Findings from a phase I study of concurrent ipilimumab and nivolumab for advanced melanoma

Yoga two to three times a week on average lowers both systolic and diastolic BP by three points

Click to access a single page summary of the most significant study results and research announcements presented.

With over 400,000 jobs from top employers, you are sure to find the right job for you.